Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
09:20am, Thursday, 08'th May 2025
Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago.
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 08'th May 2025
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline
11:07am, Thursday, 01'st May 2025
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
11:30am, Tuesday, 29'th Apr 2025
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa
Insmed To Present at the BofA Securities 2025 Health Care Conference
07:00am, Tuesday, 29'th Apr 2025
BRIDGEWATER, N.J. , April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo
Insmed: Poised For Transformation Beyond ARIKAYCE
11:58am, Friday, 25'th Apr 2025
Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 resul
Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
07:00am, Thursday, 24'th Apr 2025
BRIDGEWATER, N.J. , April 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo
—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— �
Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
07:00am, Wednesday, 23'rd Apr 2025
BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
08:00am, Tuesday, 25'th Mar 2025
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in L
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Monday, 10'th Mar 2025
BRIDGEWATER, N.J. , March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
04:19pm, Tuesday, 25'th Feb 2025
RBC Capital Markets has initiated coverage on Insmed Inc INSM, citing brensocatib's launch momentum.
International Markets and Insmed (INSM): A Deep Dive for Investors
10:15am, Monday, 24'th Feb 2025
Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a peop
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
09:40am, Friday, 21'st Feb 2025
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
